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background: The aim of this study was to define the clinical and genetic characteristics of hypertrophic cardiomyopathy (HCM) in Iceland. 
Methods: All HCM patients in Iceland between 1997-2010 were identified and invited for clinical assessment and genetic testing. Phenotypes 
were obtained from medical records and cardiac imaging. Samples were screened for the MYBPC3 c.927-2A>G mutation previously identified in two 
Icelandic families. If negative, targeted sequencing of sarcomere genes was performed. 
results: Of 180 HCM patients, 150 were alive and 137 underwent genotyping; 76 patients (55%) had MYBPC3 c.927-2A>G. Eight other variants 
in MYBPC3 and MYH7 were identified in 9 patients. Haplotype analysis confirmed MYBPC3 c.927-2A>G as a founder mutation, estimated to have 
arisen in the 15th century. The population carrier frequency is 0.36%. MYBPC3 c.927-2A>G was associated with significant phenotypic diversity. 
Carriers of MYBPC3 c.927-2A>G were younger at diagnosis (42 vs. 49 years, p=0.008), more often had ≥2 risk factors for sudden death (35% vs. 9%, 
p<0.0001) and sustained more adverse events (13% vs. 2%, p=0.029) than sarcomere mutation-negative patients. Mortality for all HCM was similar 
to an age-matched Icelandic population (Hazard Ratio 0.98 p= 0.89). HCM-related mortality (0.78%/year) occurred at a mean age of 68 compared 
to 81 years for non-HCM related mortality (p=0.022).
conclusions: In Iceland, HCM is characterized by relatively benign and low event rate clinical course. A majority of cases (55%) were caused by a 
MYBPC3 founder mutation arising approximately 550 years ago.
